BofA Securities initiates Immix Biopharma with Buy rating, citing NXC-201's potential in AL amyloidosis and peak sales near $963 million.
Bank of America (BofA) Securities initiated coverage on Immix Biopharma Inc.
(NASDAQ:IMMX), driven by NXC-201 in AL amyloidosis.
AL amyloidosis is a rare plasma cell disorder wherein abnormal plasma cells in the bone marrow overproduce misfolded antibody proteins (light chains).
These proteins clump together as amyloid deposits, progressively damaging vital organs.
Read Also: Why Is Prothena Stock Trading Lower On Tuesday?
Innovent Biologics Announces First Patient Dosed in a Phase 3 Clinical Trial of IBI3003(GPRC5D/BCMA/CD3 Tri-specific Antibody) for the Treatment of Multiple Myeloma
IGC Pharma's AHA Agentic AI Platform Reduces Alzheimer's Data Harmonization Time by 90% in Representative Workflow
In a report released yesterday, Sam Slutsky from LifeSci Capital maintained a Buy rating on Immunic, with a price target of…
Stifel Nicolaus analyst Paul Matteis maintained a Buy rating on Immunic yesterday and set a price target of $25.00.Memorial Day…
ImmunityBio shares rise after the FDA accepted ANKTIVA's sBLA for NMIBC, with Phase 2/3 data showing durable bladder cancer…
ImmunityBio Presents New Clinical and Comparative Data Across Lung and Bladder Cancer at ASCO 2026
In a report released today, Rami Katkhuda from LifeSci Capital maintained a Buy rating on Amylyx Pharmaceuticals Inc, with a…
Immunic (IMUX) stock rises premarket to $13.14 as the company names former Genentech executive Erik Lundgren as CEO. See how his…
